hokeypokey wrote:

My hair salon has an advertised rule. Wear a mask. My hairdresser said a man came in demanded a haircut but refused to wear a mask. Caused a big scene & left with no haircut. Now what did he gain ?

Quote:

Several studies have investigated respiratory droplets produced by both healthy and infected individuals when performing various activities. The transport characteristics of these droplets can vary significantly depending on their diameter.23–28 The reported droplet diameters vary widely among studies available in the literature and usually lie within the range 1 µm–500 µm,29 with a mean diameter of ?10 µm.30 The larger droplets (diameter >100 µm) are observed to follow ballistic trajectories under the effects of gravity and aerodynamic drag.20,31

Quote:

Results

Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine?+?azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%])?.

Quote:

Limitations to our analysis include the retrospective, non-randomized, non-blinded study design. Also, information on duration of symptoms prior to hospitalization was not available for analysis.

Quote:

Recent observational retrospective studies and randomized trials of hydroxychloroquine have reported variable results. (Gautret et al., 2020a, Gao et al., 2020, Gautret et al., 2020b, Jun et al., 2020, Tang et al., 2020, Chen et al., 2020, Yu et al., 2020, Geleris et al., 2020, Rosenberg et al., 2020, Magagnoli et al., 2020, Million et al., 2020) In a randomized controlled study of 62 patients from China with COVID-19, hydroxychloroquine was associated with a shortened duration of fever and time to cough and pneumonia resolution (Chen et al., 2020). In contrast, a study of 1376 consecutive hospitalized COVID-19 patients in New York that used respiratory failure as the primary endpoint found no significant reduction in the likelihood of death or intubation among those receiving hydroxychloroquine compared to those who did not. (Geleris et al., 2020) In a separate multicenter cohort study of 1438 patients from 25 hospitals in New York, no reduction in hospitalized patient mortality was observed with hydroxychloroquine treatment (Rosenberg et al., 2020). Among a number of limitations, this study included patients who were initiated on hydroxychloroquine therapy at any time during their hospitalization. In contrast, in our patient population, 82% received hydroxychloroquine within the first 24?hours of admission, and 91% within 48?hours of admission. Because treatment regimens likely varied substantially (including delayed initiation) across the 25 hospitals that contributed patients to the study, it is not surprising that the case-fatality rate among the New York patients was significantly higher than in our study.

Quote:

our results should be interpreted with some caution and should not be applied to patients treated outside of hospital settings. Our results also require further confirmation in prospective, randomized controlled trials that rigorously evaluate the safety, and efficacy of hydroxychloroquine therapy for COVID-19 in hospitalized patients.

Quote:

“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalised COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a statement, referring to large multicountry trials that the agency is leading.